Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery

Clinical mRNA delivery remains challenging, in large part because how physiology alters delivery in vivo remains underexplored. For example, mRNA delivered by lipid nanoparticles (LNPs) is being considered to treat inflammation, but whether inflammation itself changes delivery remains understudied. Relationships between immunity, endocytosis, and mRNA translation lead to hypothesize that toll-like receptor 4 (TLR4) activation reduced LNP-mediated mRNA delivery. Therefore, LNP uptake, endosomal escape, and mRNA translation with and without TLR4 activation are quantified. In vivo DNA barcoding is used to discover a novel LNP that delivers mRNA to Kupffer cells at clinical doses; unlike most LNPs, this LNP does not preferentially target hepatocytes. TLR4 activation blocks mRNA translation in all tested cell types, without reducing LNP uptake; inhibiting TLR4 or its downstream effector protein kinase R improved delivery. The discrepant effects of TLR4 on i) LNP uptake and ii) translation suggests TLR4 activation can "override" LNP targeting, even after mRNA is delivered into target cells. Given near-future clinical trials using mRNA to modulate inflammation, this highlights the need to understand inflammatory signaling in on- and off-target cells. More generally, this suggests an LNP which delivers mRNA to one inflammatory disease may not deliver mRNA to another.

[1]  Yong-soo Lee,et al.  Hepatocyte toll-like receptor 4 mediates lipopolysaccharide-induced hepcidin expression , 2017, Experimental & Molecular Medicine.

[2]  George F. Murphy,et al.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.

[3]  P. Garcez,et al.  Zika virus disrupts molecular fingerprinting of human neurospheres , 2017, Scientific Reports.

[4]  James E. Crowe,et al.  A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection , 2019, Science Immunology.

[5]  James E Dahlman,et al.  Modifying a Commonly Expressed Endocytic Receptor Retargets Nanoparticles in Vivo. , 2018, Nano letters.

[6]  L. O’Neill,et al.  Localisation and trafficking of Toll-like receptors: an important mode of regulation. , 2010, Current opinion in immunology.

[7]  Amitabha Das,et al.  High-Resolution Mapping and Dynamics of the Transcriptome, Transcription Factors, and Transcription Co-Factor Networks in Classically and Alternatively Activated Macrophages , 2018, Front. Immunol..

[8]  Christoffer Åberg,et al.  Mapping protein binding sites on the biomolecular corona of nanoparticles. , 2015, Nature nanotechnology.

[9]  Daniel G. Anderson,et al.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing , 2017, Nature Biotechnology.

[10]  Low-dose lipopolysaccharide (LPS) inhibits aggressive and augments depressive behaviours in a chronic mild stress model in mice , 2016, Journal of Neuroinflammation.

[11]  James E. Dahlman,et al.  Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands , 2019, Advanced materials.

[12]  Gaurav Sahay,et al.  Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA. , 2017, Nano letters.

[13]  E. Latz,et al.  Endocytic pathways regulate Toll‐like receptor 4 signaling and link innate and adaptive immunity , 2006, The EMBO journal.

[14]  W. Seeger,et al.  PKR regulates TLR2/TLR4-dependent signaling in murine alveolar macrophages. , 2008, American journal of respiratory cell and molecular biology.

[15]  Giuseppe Battaglia,et al.  Exploiting endocytosis for nanomedicines. , 2013, Cold Spring Harbor perspectives in biology.

[16]  Huajian Gao,et al.  Physical Principles of Nanoparticle Cellular Endocytosis. , 2015, ACS nano.

[17]  K. Chien,et al.  Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine , 2018, Molecular therapy. Methods & clinical development.

[18]  Kimberly J. Hassett,et al.  Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Robert Langer,et al.  Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.

[20]  Philip J. Santangelo,et al.  A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation. , 2018, Nano letters.

[21]  James E. Dahlman,et al.  Using Large Datasets to Understand Nanotechnology , 2019, Advanced materials.

[22]  Justin M. Richner,et al.  Modified mRNA Vaccines Protect against Zika Virus Infection , 2017, Cell.

[23]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[24]  Gaurav Sahay,et al.  Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. , 2012, Journal of the American Chemical Society.

[25]  T. Cullen,et al.  Mechanisms of Toll-like Receptor 4 Endocytosis Reveal a Common Immune-Evasion Strategy Used by Pathogenic and Commensal Bacteria. , 2015, Immunity.

[26]  Robert Langer,et al.  Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse , 2017, Molecular therapy. Nucleic acids.

[27]  Dan Peer,et al.  Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes , 2018, Nature Communications.

[28]  R. Xu,et al.  Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. , 2007, Gastroenterology.

[29]  Fengjuan Wang,et al.  The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[30]  Philip J. Santangelo,et al.  High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing , 2018, Proceedings of the National Academy of Sciences.

[31]  Robert Langer,et al.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.

[32]  Alain Michault,et al.  Type I IFN controls chikungunya virus via its action on nonhematopoietic cells , 2010, The Journal of experimental medicine.

[33]  Martyn F. Symmons,et al.  Assembly and localization of Toll-like receptor signalling complexes , 2014, Nature Reviews Immunology.

[34]  O. Benveniste,et al.  Innate and Adaptive Immune Response in Fabry Disease. , 2015, JIMD reports.

[35]  A. Thomson,et al.  Low TLR4 Expression by Liver Dendritic Cells Correlates with Reduced Capacity to Activate Allogeneic T Cells in Response to Endotoxin1 , 2005, The Journal of Immunology.

[36]  Philip J. Santangelo,et al.  Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA–protein correlations at the level of single cells , 2017, Nucleic acids research.

[37]  E. Domingo,et al.  Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action , 2006, Microbiology and Molecular Biology Reviews.

[38]  Judy Lieberman,et al.  Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown , 2015, Nature Biotechnology.

[39]  Michael J. T. Stubbington,et al.  The Human Cell Atlas: from vision to reality , 2017, Nature.

[40]  S. Adams,et al.  Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma , 2015, Cancer Immunology Research.

[41]  S. Akira,et al.  TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β , 2008, Nature Immunology.

[42]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[43]  C. A. Mora,et al.  Detecting and Number Counting of Single Engineered Nanoparticles by Digital Particle Polymerase Chain Reaction. , 2015, ACS nano.

[44]  Jonathan L. Kirschman,et al.  Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection , 2018, Nature Communications.

[45]  G. Su,et al.  Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protein and toll‐like receptor 4 , 2000, Hepatology.

[46]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[47]  R. Coler,et al.  A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines , 2017, Scientific Reports.

[48]  Sarah Seifert,et al.  Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.

[49]  Kimberly J. Hassett,et al.  Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[51]  K. G. Rajeev,et al.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  James E Dahlman,et al.  Cell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles , 2019, Cellular and molecular bioengineering.

[53]  James E. Dahlman,et al.  Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution. , 2018, Journal of the American Chemical Society.

[54]  Carmen J Gil,et al.  Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery. , 2018, ACS nano.

[55]  A. J. Tavares,et al.  Effect of removing Kupffer cells on nanoparticle tumor delivery , 2017, Proceedings of the National Academy of Sciences.

[56]  Alison J. Scott,et al.  The TLR4 antagonist Eritoran protects mice from lethal influenza infection , 2013, Nature.

[57]  Warren C W Chan,et al.  Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. , 2012, Chemical Society reviews.

[58]  S. Jiang,et al.  The emerging role of Toll-like receptor 4 in myocardial inflammation , 2016, Cell Death and Disease.

[59]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[60]  A. Leite-Moreira,et al.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases , 2010, Hepatology international.

[61]  Khalid A. Hajj,et al.  Tools for translation: non-viral materials for therapeutic mRNA delivery , 2017 .

[62]  C. Lukacs,et al.  Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates. , 2019, American journal of human genetics.

[63]  James E. Dahlman,et al.  Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses , 2019, Advanced materials.